Table 2.

Prevalence of Pretransplantation Comorbidities and Cumulative Incidence of New Post-HCT Late Effects at 5 Years After HCT, With Median and IQR of Time to Diagnosis

Pretransplantation Comorbidities and/or New Post-HCT Late Effects	Autologous					Allogeneic					P for Autologous vAllogeneic Transplantation
	Pretransplantation Prevalence (%)	Cumulative Incidence Since Transplantation		Days to Diagnosis		Pretransplantation Prevalence (%)	Cumulative Incidence Since Transplantation		Days To Diagnosis Median (IQR)
		%	SE	Median	IQR		%	SE	Median	IQR
Avascular necrosis	0.2	4.3	1.3	411	86-811	0.5	4.6	0.9	514	340-635	.32
Joint replacement	1.8	4.2	1.3	1,098	463-1,199	1.4	3.0	0.8	645	362-766	.92
Osteoporosis	2.4	9.7	1.7	420	229-500	1.4	23.0	1.9	364	223-464	< .001
Thyroid disease	7.5	14.2	1.8	353	204-679	9.8	13.3	1.6	385	286-612	.66
Diabetes mellitus	6.1	3.0	1.0	580	212-1,104	8.3	22.9	1.8	216	153-353	< .001
Adrenal insufficiency	0.2	1.3	0.8	1,236	140-1,437	0.2	13.4	1.5	340	166-413	< .001
Cerebrovascular disease	0.6	1.1	0.5	137	137-177	1.2	1.8	0.6	476	143-716	.51
Coronary artery disease	3.5	1.9	1.0	1,444	778-1,447	3.0	2.7	0.8	453	329-1,059	.14
Iron overload	0.2	0.7	0.4	392	334-572	2.2	25.4	2.0	363	227-432	< .001
Obstructive/restrictive lung disease	1.6	8.2	1.3	369	330-392	1.5	36.9	2.1	363	235-504	< .001
Organ transplantation	0	0.3	0.3	803		0.2	—		—		.19
Suicide or suicide attempt	0.2	0.3	0.3	737		0.7	0.9	0.5	671	393-1,045	.27
Deep venous thrombosis(not catheter associated)	7.5	5.6	1.1	137	67-371	3.7	10.9	1.4	343	210-572	.01
Dialysis	1.4	2.3	0.8	204	77-776	0	2.0	0.6	460	362-662	.94

Abbreviations: HCT, hematopoietic cell transplantation; IQR, interquartile range.